General Information of Drug Combination (ID: DC17GNA)

Drug Combination Name
Clindamycin Cefazolin
Indication
Disease Entry Status REF
Supracondylar Humerus Fracture Phase 4 [1]
Component Drugs Clindamycin   DM15HL8 Cefazolin   DMPDYFR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Clindamycin
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Aspiration pneumonia N.A. Approved [3]
Bacteremia 1A73 Approved [3]
Bacterial vaginosis MF3A Approved [3]
Pleural empyema N.A. Approved [3]
Staphylococcal pneumonia N.A. Approved [3]
Staphylococcus aureus infection N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Pelvic inflammatory disease GA05 Investigative [3]
Clindamycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [6]
------------------------------------------------------------------------------------
Clindamycin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Beta-lactamase (blaB) DEMSNER A4LA84_EDWTA Metabolism [8]
------------------------------------------------------------------------------------
Clindamycin Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [9]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Affects Expression [10]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Affects Expression [10]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Increases Expression [11]
------------------------------------------------------------------------------------
Indication(s) of Cefazolin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Cholangitis N.A. Approved [4]
Staphylococcal pneumonia N.A. Approved [4]
Cefazolin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [12]
------------------------------------------------------------------------------------
Cefazolin Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [14]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [15]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [16]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Cefazolin Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Metabolism [17]
Beta-lactamase (blaB) DEP0IWS A0A378EHS6_KLEPR Metabolism [18]
Beta-lactamase (blaB) DE7IH52 AMPC_CITFR Metabolism [19]
Beta-lactamase (blaB) DENJ2SQ BLAB_BACFG Metabolism [20]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Burn DCVPHSM N. A. Phase 4 [21]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03261830) Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Clindamycin FDA Label
4 Cefazolin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065244.
6 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
7 In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
8 Comparison of antimicrobial susceptibility, beta-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol. 1993 Oct;39(4):273-81.
9 A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97.
10 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
11 Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. Toxicol Sci. 2010 Jul;116(1):140-50. doi: 10.1093/toxsci/kfq085. Epub 2010 Mar 25.
12 Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
13 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
14 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
15 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
16 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
17 Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
18 Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
19 Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
20 Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
21 ClinicalTrials.gov (NCT04516148) A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting